Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01281631 is registered in ClinicalTrials.gov with Neuraltus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Neuraltus Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- September 30, 2012
- Enrollment
- 136 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.